查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1472279

可吸入一氧化氮市場：依應用分類：2023-2032 年全球機會分析與產業預測

Inhaled Nitric Oxide Market By Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease, Acute Respiratory Distress Syndrome, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 179 Pages | 商品交期: 2-3個工作天內

價格

2022年全球吸入一氧化氮市場價值為8億美元，預估2023年至2032年複合年成長率為7.7%，至2032年達到16億美元。

吸入一氧化氮是一種治療氣體，用於管理和治療新生兒缺氧性呼吸衰竭和持續性肺動脈高壓。吸入一氧化氮是一種選擇性肺血管擴張劑，可改善肺部通氣良好區域的血流，改善通氣和灌注匹配，並降低肺動脈高壓。主要作用機轉是活化平滑肌細胞中的鳥苷酸環化酶，導致環磷酸鳥苷 (cGMP) 增加和隨後的血管舒張。

吸入一氧化氮市場-IMG1

吸入一氧化氮市場的成長歸因於吸入一氧化氮的廣泛採用，以應對新生兒缺氧性呼吸衰竭和慢性阻塞性肺病盛行率的上升。吸入一氧化氮治療新生兒缺氧性呼吸衰竭的高採用率是推動吸入一氧化氮市場成長的關鍵因素。近年來，吸入一氧化氮已成為新生兒醫學的重要治療性介入，特別是因缺氧而出現呼吸窘迫的嬰兒。例如，美國食品藥物管理局於 1999 年推出 INOmax，並於 2019 年推出 Genosyl，用於治療患有缺氧性呼吸衰竭並伴隨肺動脈高壓臨床或超音波心動圖核准的足月和足月嬰兒（妊娠超過34 週）。

新生兒在適應子宮外的生活方面經常面臨挑戰，缺氧性呼吸衰竭是這段過渡時期的重要問題。吸入一氧化氮具有血管舒張作用，選擇性作用於肺血管，擴張肺血管，改善供氧，降低肺動脈高壓。它在增強氧氣供應同時最大限度地減少潛在的全身副作用方面的有效性已被醫療專業人士廣泛接受。

由於早產和先天缺陷等因素，新生兒缺氧性呼吸衰竭的盛行率不斷增加，導致對有效治療方案的需求激增，進一步推動了吸入一氧化氮的採用。此外，醫療保健提供者對吸入一氧化氮在預防和減輕缺氧引起的併發症方面的益處的認知不斷提高，這有助於將其廣泛納入新生兒加護治療方案中。因此，吸入一氧化氮治療新生兒缺氧性呼吸衰竭的高採用率有望促進吸入一氧化氮的成長。

此外，慢性阻塞性肺病盛行率的上升預計將推動市場成長。慢性阻塞性肺病是一種由長期暴露於有害顆粒和氣體（主要是菸草煙霧中的顆粒和氣體）引起的進行性和衰弱性呼吸系統疾病，在全球範圍內已達到令人震驚的水平。例如，國家醫學圖書館 2022 年的一份報告稱，全球 40 歲以上人群中慢性阻塞性肺病(COPD) 的盛行率為 10.1%。隨著慢性阻塞性肺病的盛行率持續上升，迫切需要有效的治療性介入來緩解症狀並改善受影響者的整體生活品質。由於吸入一氧化氮在治療慢性阻塞性肺病等呼吸系統疾病方面的潛力，其採用率正在迅速增加。一氧化氮的血管舒張和發炎作用使其成為改善肺功能的有希望的候選者。因此，慢性阻塞性肺病盛行率的上升預計將顯著促進市場成長。

可吸入一氧化氮市場按應用和地區細分。依用途分為新生兒呼吸治療、慢性阻塞性肺病（COPD）、急性呼吸窘迫症候群（ARDS）等。依地區分類，包括北美（美國、加拿大、墨西哥）、歐洲（德國、法國、英國、義大利等歐洲地區）、亞太地區（日本、澳洲等亞太地區）、拉丁美洲（拉丁美洲、中東其他地區）,非洲）。

相關人員的主要利益

  • 該報告提供了 2022 年至 2032 年吸入一氧化氮市場分析的細分市場、當前趨勢、估計/趨勢和動態的定量分析，並確定了當前吸入一氧化氮市場的機會。
  • 它提供市場研究以及與市場促進因素、市場限制和市場機會相關的資訊。
  • 波特的五力分析強調買家和供應商幫助相關人員做出利潤驅動的商業決策並加強供應商-買家網路的潛力。
  • 吸入一氧化氮市場區隔的詳細分析將有助於確定市場機會。
  • 每個地區的主要國家都根據其對全球市場的收益貢獻繪製了地圖。
  • 市場參與企業定位有助於基準化分析，並提供對市場參與企業當前地位的清晰了解。
  • 研究報告包括對區域和全球可吸入一氧化氮市場趨勢、主要企業、細分市場、應用領域和市場成長策略的分析。

可以使用此報告進行報告客製化（可能需要額外費用和時間表）

  • 國家、區域和全球各級的患者/流行病學資料
  • 監管指引
  • 根據客戶興趣新增其他公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 擴大公司簡介列表
  • 歷史市場資料
  • SWOT分析

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 關鍵投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
      • 吸入一氧化氮用於嬰幼兒和新生兒肺部疾病管理的採用率很高
      • 呼吸道疾病盛行率上升
      • 醫療基礎設施的進步
    • 抑制因素
      • 吸入一氧化氮高成本
    • 機會
      • 積極進行吸入一氧化氮的研發活動
  • 市場佔有率分析

第4章吸入一氧化氮市場：依應用分類

  • 概述
  • 新生兒呼吸治療
  • 慢性阻塞性肺病
  • 急性呼吸窘迫症候群
  • 其他

第5章一氧化氮吸入市場：按地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 其他
  • 亞太地區
    • 日本
    • 澳洲
    • 其他
  • 拉丁美洲
    • 拉丁美洲
    • 中東/非洲

第6章 競爭狀況

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2022年主要企業定位

第7章 公司簡介

  • Air Liquide SA
  • Linde PLC
  • Mallinckrodt plc
  • Vero Biotech LLC
  • SOL Group
  • Air Water Inc.
  • Chemix Specialty Gases and Equipment
  • Nippon Sanso Holdings Corporation
  • Chengdu Taiyu Industrial Gases Co., Ltd.
  • Sichuan Salman Chemical Products Co., Ltd
Product Code: A02681

The global inhaled nitric oxide market was valued at $0.8 billion in 2022, and is projected to reach $1.6 billion by 2032, growing at a CAGR of 7.7% from 2023 to 2032

Inhaled nitric oxide is a therapeutic gas used to manage and treat hypoxic respiratory failure or persistent pulmonary hypertension in newborns. Inhaled nitric oxide is a selective pulmonary vasodilator, meaning it helps improve blood flow to well-ventilated areas of the lung, thus improving ventilation-perfusion matching and reducing pulmonary hypertension. The primary mechanism of action involves the activation of guanylate cyclase in smooth muscle cells, leading to an increase in cyclic guanosine monophosphate (cGMP) and subsequent vasodilation.

Inhaled Nitric Oxide Market - IMG1

The growth of the inhaled nitric oxide market is attributed to the high adoption of the inhaled nitric oxide for neonatal hypoxic respiratory failure and rise in prevalence of chronic obstructive pulmonary disease. The high adoption of inhaled nitric oxide for neonatal hypoxic respiratory failure stands out as a major driver propelling the growth of the inhaled nitric oxide market. In recent years, inhaled nitric oxide has emerged as a crucial therapeutic intervention in the neonatal care landscape, particularly for infants experiencing respiratory distress due to hypoxic conditions. For instance, the U.S. Food and Drug Administration has approved INOmax in 1999 and Genosyl in 2019 for term and near-term infants (>34 weeks' gestation) with hypoxic respiratory failure associated with clinical or echocardiographic signs of pulmonary hypertension to improve oxygenation and lower the risk of extracorporeal membrane oxygenation.

Neonates often face challenges in adapting to extrauterine life, and hypoxic respiratory failure is a critical concern during this transitional period. Inhaled nitric oxide, with its vasodilatory properties, acts selectively on the pulmonary vasculature, improving oxygenation by dilating the pulmonary vessels and reducing pulmonary hypertension. Its efficacy in enhancing oxygen delivery while minimizing potential systemic side effects has garnered widespread acceptance among healthcare professionals.

The increased prevalence of neonatal hypoxic respiratory failure, attributed to factors such as premature birth and congenital disorders, has led to a surge in the demand for effective treatment options, further driving the adoption of inhaled nitric oxide. Moreover, the growth in awareness among healthcare providers about the benefits of inhaled nitric oxide in preventing or mitigating hypoxic-induced complications has contributed to widespread incorporation of inhaled nitric oxide into neonatal intensive care protocols. Thus, the high adoption of the inhaled nitric oxide for neonatal hypoxic respiratory failure is expected to drive the growth of the inhaled nitric oxide.

Furthermore, rise in prevalence of chronic obstructive pulmonary disease is expected to drive the growth of the market. Chronic obstructive pulmonary disease, a progressive and debilitating respiratory condition primarily caused by prolonged exposure to harmful particles or gases, such as those found in cigarette smoke, is reaching alarming levels globally. For instance, according to the 2022 report by the National Library of Medicine, it was reported that chronic obstructive pulmonary disease (COPD) has a worldwide prevalence of 10.1% in people aged 40 years or older. As the incidence of COPD continues to rise, there is an urgent demand for effective therapeutic interventions that can alleviate the symptoms and enhance the overall quality of life for affected individuals. The adoption of inhaled nitric oxide has surged owing to its potential in managing respiratory disorders, including COPD. The vasodilatory and anti-inflammatory properties of nitric oxide make it a promising candidate for improving pulmonary function. Thus, the rise in the prevalence of chronic obstructive pulmonary disease is expected to contribute significantly to the growth of the market.

The inhaled nitric oxide market is segmented on the basis of application, and region. By application, the market is classified into neonatal respiratory treatment, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, and rest of Europe), Asia-Pacific (Japan, Australia, and rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).

Major key players that operate in the global inhaled nitric oxide market are Air Liquide S.A, Linde Plc, Mallinckrodt Plc, Vero Biotech LLC, Chemix Specialty Gases and Equipment, Air Water Inc, Sichuan Salman Chemical Products Co., Ltd, Linde PLC, SOL Group, Nippon Sanso Holdings Corporation and Chengdu Taiyu Industrial Gases Co., Ltd.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the inhaled nitric oxide market analysis from 2022 to 2032 to identify the prevailing inhaled nitric oxide market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the inhaled nitric oxide market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global inhaled nitric oxide market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Application

  • Neonatal Respiratory Treatment
  • Chronic Obstructive Pulmonary Disease
  • Acute Respiratory Distress Syndrome
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East And Africa

Key Market Players:

    • Air Liquide S.A.
    • Mallinckrodt plc
    • Chemix Specialty Gases and Equipment
    • Vero Biotech LLC
    • Air Water Inc.
    • Sichuan Salman Chemical Products Co., Ltd
    • Linde PLC
    • SOL Group
    • Nippon Sanso Holdings Corporation
    • Chengdu Taiyu Industrial Gases Co., Ltd.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. High adoption of the inhaled nitric oxide for management of pulmonary disorders in the infants and newborns.
      • 3.4.1.2. Rise in prevalence of the respiratory disorders.
      • 3.4.1.3. Advancements in healthcare infrastructure.
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of inhaled nitric oxide.
    • 3.4.3. Opportunities
      • 3.4.3.1. High research and development activities for inhaled nitric oxide.
  • 3.5. Market Share Analysis

CHAPTER 4: INHALED NITRIC OXIDE MARKET, BY APPLICATION

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Neonatal Respiratory Treatment
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Chronic Obstructive Pulmonary Disease
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Acute Respiratory Distress Syndrome
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: INHALED NITRIC OXIDE MARKET, BY REGION

  • 5.1. Overview
    • 5.1.1. Market size and forecast By Region
  • 5.2. North America
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by Application
    • 5.2.3. Market size and forecast, by country
      • 5.2.3.1. U.S.
      • 5.2.3.1.1. Market size and forecast, by Application
      • 5.2.3.2. Canada
      • 5.2.3.2.1. Market size and forecast, by Application
      • 5.2.3.3. Mexico
      • 5.2.3.3.1. Market size and forecast, by Application
  • 5.3. Europe
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by Application
    • 5.3.3. Market size and forecast, by country
      • 5.3.3.1. Germany
      • 5.3.3.1.1. Market size and forecast, by Application
      • 5.3.3.2. France
      • 5.3.3.2.1. Market size and forecast, by Application
      • 5.3.3.3. UK
      • 5.3.3.3.1. Market size and forecast, by Application
      • 5.3.3.4. Italy
      • 5.3.3.4.1. Market size and forecast, by Application
      • 5.3.3.5. Rest of Europe
      • 5.3.3.5.1. Market size and forecast, by Application
  • 5.4. Asia-Pacific
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by Application
    • 5.4.3. Market size and forecast, by country
      • 5.4.3.1. Japan
      • 5.4.3.1.1. Market size and forecast, by Application
      • 5.4.3.2. Australia
      • 5.4.3.2.1. Market size and forecast, by Application
      • 5.4.3.3. Rest of Asia-Pacific
      • 5.4.3.3.1. Market size and forecast, by Application
  • 5.5. LAMEA
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by Application
    • 5.5.3. Market size and forecast, by country
      • 5.5.3.1. Latin America
      • 5.5.3.1.1. Market size and forecast, by Application
      • 5.5.3.2. Middle East And Africa
      • 5.5.3.2.1. Market size and forecast, by Application

CHAPTER 6: COMPETITIVE LANDSCAPE

  • 6.1. Introduction
  • 6.2. Top winning strategies
  • 6.3. Product mapping of top 10 player
  • 6.4. Competitive dashboard
  • 6.5. Competitive heatmap
  • 6.6. Top player positioning, 2022

CHAPTER 7: COMPANY PROFILES

  • 7.1. Air Liquide S.A.
    • 7.1.1. Company overview
    • 7.1.2. Key executives
    • 7.1.3. Company snapshot
    • 7.1.4. Operating business segments
    • 7.1.5. Product portfolio
    • 7.1.6. Business performance
  • 7.2. Linde PLC
    • 7.2.1. Company overview
    • 7.2.2. Key executives
    • 7.2.3. Company snapshot
    • 7.2.4. Operating business segments
    • 7.2.5. Product portfolio
    • 7.2.6. Business performance
    • 7.2.7. Key strategic moves and developments
  • 7.3. Mallinckrodt plc
    • 7.3.1. Company overview
    • 7.3.2. Key executives
    • 7.3.3. Company snapshot
    • 7.3.4. Operating business segments
    • 7.3.5. Product portfolio
    • 7.3.6. Business performance
  • 7.4. Vero Biotech LLC
    • 7.4.1. Company overview
    • 7.4.2. Key executives
    • 7.4.3. Company snapshot
    • 7.4.4. Operating business segments
    • 7.4.5. Product portfolio
  • 7.5. SOL Group
    • 7.5.1. Company overview
    • 7.5.2. Key executives
    • 7.5.3. Company snapshot
    • 7.5.4. Operating business segments
    • 7.5.5. Product portfolio
    • 7.5.6. Business performance
    • 7.5.7. Key strategic moves and developments
  • 7.6. Air Water Inc.
    • 7.6.1. Company overview
    • 7.6.2. Key executives
    • 7.6.3. Company snapshot
    • 7.6.4. Operating business segments
    • 7.6.5. Product portfolio
    • 7.6.6. Business performance
  • 7.7. Chemix Specialty Gases and Equipment
    • 7.7.1. Company overview
    • 7.7.2. Key executives
    • 7.7.3. Company snapshot
    • 7.7.4. Operating business segments
    • 7.7.5. Product portfolio
  • 7.8. Nippon Sanso Holdings Corporation
    • 7.8.1. Company overview
    • 7.8.2. Key executives
    • 7.8.3. Company snapshot
    • 7.8.4. Operating business segments
    • 7.8.5. Product portfolio
    • 7.8.6. Business performance
  • 7.9. Chengdu Taiyu Industrial Gases Co., Ltd.
    • 7.9.1. Company overview
    • 7.9.2. Key executives
    • 7.9.3. Company snapshot
    • 7.9.4. Operating business segments
    • 7.9.5. Product portfolio
  • 7.10. Sichuan Salman Chemical Products Co., Ltd
    • 7.10.1. Company overview
    • 7.10.2. Key executives
    • 7.10.3. Company snapshot
    • 7.10.4. Operating business segments
    • 7.10.5. Product portfolio

LIST OF TABLES

  • TABLE 01. GLOBAL INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 02. INHALED NITRIC OXIDE MARKET FOR NEONATAL RESPIRATORY TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. INHALED NITRIC OXIDE MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. INHALED NITRIC OXIDE MARKET FOR ACUTE RESPIRATORY DISTRESS SYNDROME, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. INHALED NITRIC OXIDE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. INHALED NITRIC OXIDE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. NORTH AMERICA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 08. NORTH AMERICA INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 09. U.S. INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 10. CANADA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 11. MEXICO INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 12. EUROPE INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 13. EUROPE INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 14. GERMANY INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 15. FRANCE INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 16. UK INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 17. ITALY INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 18. REST OF EUROPE INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 19. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 20. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 21. JAPAN INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 22. AUSTRALIA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. REST OF ASIA-PACIFIC INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 24. LAMEA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 25. LAMEA INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 26. LATIN AMERICA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 27. MIDDLE EAST AND AFRICA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 28. AIR LIQUIDE S.A.: KEY EXECUTIVES
  • TABLE 29. AIR LIQUIDE S.A.: COMPANY SNAPSHOT
  • TABLE 30. AIR LIQUIDE S.A.: PRODUCT SEGMENTS
  • TABLE 31. AIR LIQUIDE S.A.: PRODUCT PORTFOLIO
  • TABLE 32. LINDE PLC: KEY EXECUTIVES
  • TABLE 33. LINDE PLC: COMPANY SNAPSHOT
  • TABLE 34. LINDE PLC: PRODUCT SEGMENTS
  • TABLE 35. LINDE PLC: PRODUCT PORTFOLIO
  • TABLE 36. LINDE PLC: KEY STRATERGIES
  • TABLE 37. MALLINCKRODT PLC: KEY EXECUTIVES
  • TABLE 38. MALLINCKRODT PLC: COMPANY SNAPSHOT
  • TABLE 39. MALLINCKRODT PLC: PRODUCT SEGMENTS
  • TABLE 40. MALLINCKRODT PLC: PRODUCT PORTFOLIO
  • TABLE 41. VERO BIOTECH LLC: KEY EXECUTIVES
  • TABLE 42. VERO BIOTECH LLC: COMPANY SNAPSHOT
  • TABLE 43. VERO BIOTECH LLC: PRODUCT SEGMENTS
  • TABLE 44. VERO BIOTECH LLC: PRODUCT PORTFOLIO
  • TABLE 45. SOL GROUP: KEY EXECUTIVES
  • TABLE 46. SOL GROUP: COMPANY SNAPSHOT
  • TABLE 47. SOL GROUP: PRODUCT SEGMENTS
  • TABLE 48. SOL GROUP: PRODUCT PORTFOLIO
  • TABLE 49. SOL GROUP: KEY STRATERGIES
  • TABLE 50. AIR WATER INC.: KEY EXECUTIVES
  • TABLE 51. AIR WATER INC.: COMPANY SNAPSHOT
  • TABLE 52. AIR WATER INC.: PRODUCT SEGMENTS
  • TABLE 53. AIR WATER INC.: PRODUCT PORTFOLIO
  • TABLE 54. CHEMIX SPECIALTY GASES AND EQUIPMENT: KEY EXECUTIVES
  • TABLE 55. CHEMIX SPECIALTY GASES AND EQUIPMENT: COMPANY SNAPSHOT
  • TABLE 56. CHEMIX SPECIALTY GASES AND EQUIPMENT: PRODUCT SEGMENTS
  • TABLE 57. CHEMIX SPECIALTY GASES AND EQUIPMENT: PRODUCT PORTFOLIO
  • TABLE 58. NIPPON SANSO HOLDINGS CORPORATION: KEY EXECUTIVES
  • TABLE 59. NIPPON SANSO HOLDINGS CORPORATION: COMPANY SNAPSHOT
  • TABLE 60. NIPPON SANSO HOLDINGS CORPORATION: PRODUCT SEGMENTS
  • TABLE 61. NIPPON SANSO HOLDINGS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 62. CHENGDU TAIYU INDUSTRIAL GASES CO., LTD.: KEY EXECUTIVES
  • TABLE 63. CHENGDU TAIYU INDUSTRIAL GASES CO., LTD.: COMPANY SNAPSHOT
  • TABLE 64. CHENGDU TAIYU INDUSTRIAL GASES CO., LTD.: PRODUCT SEGMENTS
  • TABLE 65. CHENGDU TAIYU INDUSTRIAL GASES CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 66. SICHUAN SALMAN CHEMICAL PRODUCTS CO., LTD: KEY EXECUTIVES
  • TABLE 67. SICHUAN SALMAN CHEMICAL PRODUCTS CO., LTD: COMPANY SNAPSHOT
  • TABLE 68. SICHUAN SALMAN CHEMICAL PRODUCTS CO., LTD: PRODUCT SEGMENTS
  • TABLE 69. SICHUAN SALMAN CHEMICAL PRODUCTS CO., LTD: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. INHALED NITRIC OXIDE MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF INHALED NITRIC OXIDE MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN INHALED NITRIC OXIDE MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN INHALED NITRIC OXIDE MARKET (2023-2032)
  • FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 07. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL INHALED NITRIC OXIDE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR NEONATAL RESPIRATORY TREATMENT, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR ACUTE RESPIRATORY DISTRESS SYNDROME, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. INHALED NITRIC OXIDE MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 17. U.S. INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 18. CANADA INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 19. MEXICO INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 20. GERMANY INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 21. FRANCE INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 22. UK INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. ITALY INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. REST OF EUROPE INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. JAPAN INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. AUSTRALIA INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. REST OF ASIA-PACIFIC INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. LATIN AMERICA INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. MIDDLE EAST AND AFRICA INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. TOP WINNING STRATEGIES, BY YEAR (2020-2021)
  • FIGURE 31. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2021)
  • FIGURE 32. TOP WINNING STRATEGIES, BY COMPANY (2020-2021)
  • FIGURE 33. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 34. COMPETITIVE DASHBOARD
  • FIGURE 35. COMPETITIVE HEATMAP: INHALED NITRIC OXIDE MARKET
  • FIGURE 36. TOP PLAYER POSITIONING, 2022
  • FIGURE 37. AIR LIQUIDE S.A.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 38. AIR LIQUIDE S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 39. AIR LIQUIDE S.A.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 40. LINDE PLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 41. LINDE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 42. LINDE PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 43. MALLINCKRODT PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. MALLINCKRODT PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 45. MALLINCKRODT PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 46. SOL GROUP: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. SOL GROUP: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 48. SOL GROUP: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 49. AIR WATER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. AIR WATER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 51. NIPPON SANSO HOLDINGS CORPORATION: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. NIPPON SANSO HOLDINGS CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)